comparemela.com

Latest Breaking News On - Initial public offerings - Page 14 : comparemela.com

Goldman Sachs could profit as IPO and merger activity climbs: analyst

Edward Jones analyst James Shanahan initiated coverage of Goldman with a buy rating and added it to U.S. Stock Focus List.

James shanahanEdward jonesGoldman sachsSp financial servicesGoldman sachs group incSp financial services indexGoldman sachs groupDow jones industrial averageWall streetFocus listIncome buyGoldman sachs chief executive david solomonArticle normalFinancial investment servicesInvestment bankingSecurity brokering dealing

SolarMax Technology Shares Rise After IPO Pricing

By Josh Beckerman SolarMax Technology shares were recently at $5.36 in their Nasdaq debut, after an initial public offering of 4.5 million shares priced at.

Josh beckermanSolarmax technologyGmax technologyArticle normalIndustrial goodsRenewable energy equipmentCorporate changesStock listingsCorporate fundingShare capitalInitial public offeringsCorporate actionsCorporate industrial newsStock pricingsEquity marketsCommodity financial market news

AMD CEO Lisa Su just sold $20 million in stock Was it opportunistic ?

Su sold non-stock-option shares in a departure from her recent market activity, but the company says the distinction is a reach.

Ben silvermanLisa suExchange committeeDevices incAdvanced micro devicesArticle normalComputers electronicsFinancial servicesIndustrial electronicsIndustrial goodsInvesting securitiesCorporate changesStock listingsCorporate fundingShare capitalInitial public offerings

SolarMax Surges in Debut, Long After First Efforts Toward IPO

By Josh Beckerman SolarMax Technology debuted on Nasdaq Tuesday, following years of steps toward a public listing, with shares recently trading up 47% from.

Josh beckermanSolarmax technologyGmax technologyNasdaq tuesdayArticle normalBusiness consumer servicesIndustrial goodsRenewable energy equipmentShell companyCorporate changesStock listingsCorporate fundingShare capitalInitial public offeringsCorporate actionsCorporate industrial news

Everyone s Talking About These 2 Biotech IPO Stocks, But Are They Buys?

The market's excited for these stocks, but there's no rush to buy them.

National cancer instituteNational institutes of healthDrug administrationNational institutesKyverna therapeuticsMotley fool stock advisorStock advisorClinical trialsInitial public offeringsHistorical performanceFast track designation

vimarsana © 2020. All Rights Reserved.